Metabolomics and Small Molecule Profiling: Sample Collection Considerations

Metabolomics — the comprehensive analysis of small molecules (<1,500 Da) including amino acids, lipids, carbohydrates, organic acids, nucleotides, and xenobiotic metabolites — gives systems-level insight into cellular metabolism, disease pathophysiology, and therapeutic response. Genomics reveals static blueprints and transcriptomics captures intermediate states. Metabolomics reflects the ultimate functional readout, integrating genetic, transcriptional, translational, and post-translational regulation with environmental influences like diet, microbiome, and drug exposure.[1]

This proximity to phenotype makes metabolomics powerful for biomarker discovery, mechanistic work, and precision medicine across nearly every disease area. It also makes it uniquely vulnerable to pre-analytical artifacts. Metabolite pools turn over rapidly, with concentrations shifting within seconds to minutes of specimen collection.

The human metabolome spans an estimated 100,000+ chemical entities, from simple molecules like glucose and lactate to complex lipids with dozens of carbons. Mass spectrometry-based metabolomics routinely quantifies 500–2,000 metabolites per sample across central carbon metabolism, amino acid pathways, lipid species, nucleotide pools, and specialized metabolites.[2]

Different metabolite classes have very different stability. Some are stable for days at room temperature; others degrade within minutes unless specimens are immediately processed and frozen. This heterogeneity demands rigorous standardization of collection, processing, and storage so measured profiles reflect true biology rather than handling artifacts.

At Sanguine, our metabolomics expertise covers protocol optimization for diverse specimen types and analytical platforms. Human Plasma collected in EDTA tubes with immediate cold processing preserves most metabolite classes. Human Serum offers an alternative matrix for applications where clotting activates metabolically relevant pathways. Specialized protocols use metabolite stabilizers, rapid quenching, and temperature control to limit ex vivo metabolic activity.[3] Our distributed processing network across the United States enables <4 hour collection-to-freezer timelines for labile metabolites, with detailed genomic annotation from study design to receipt of samples.

Pre-Analytical Variables in Metabolomics

Collection Timing and Patient Preparation

Circulating metabolite concentrations shift with food intake, physical activity, circadian rhythm, and stress. If collection conditions are not standardized, this creates substantial pre-analytical variability.

Postprandial changes are especially dramatic. Glucose, insulin, amino acids, and lipids can all rise 50–500% within 1–4 hours of a meal.[4] These are normal responses to feeding, not pathology, yet they confound cross-sectional and longitudinal studies performed at inconsistent postprandial states. Fasting collection (typically an 8–12 hour overnight fast) removes these acute perturbations and captures basal metabolic states.

Circadian rhythms affect many metabolites, including cortisol, melatonin metabolites, and certain amino acids, with 2–3 fold morning-to-evening variation for some species.[5] Standardizing collection to one time of day (typically 8–10 AM) minimizes this. Studies specifically investigating circadian metabolism may instead sample at multiple timepoints over 24 hours under carefully controlled conditions.

Medications alter metabolite profiles through direct drug-metabolite contributions and pharmacological effects on endogenous metabolism. Ideally, subjects discontinue medications for appropriate washout periods before baseline profiling, though this is often impractical or unethical for patients on continuous therapy.[6] Comprehensive medication documentation — drug names, dosages, and timing relative to collection — enables post-acquisition correction or subgroup analyses.

Anticoagulant Selection

Plasma anticoagulant choice strongly influences metabolomic profiles. It can interfere with analytical platforms, contribute anticoagulant metabolites, and differentially affect residual cellular activity during processing.

EDTA plasma is the most widely used matrix for metabolomics, with excellent stability and minimal interference for most mass spectrometry platforms.[7] One caveat: EDTA chelates divalent cations including calcium and magnesium, which can affect certain enzymatic reactions and create artifactual shifts in specific metabolites.

Anticoagulant Comparison for Metabolomics:

• EDTA Plasma: Preferred for most applications; minimal interference, good stability; our standard Human Plasma collection.
• Heparin Plasma: Alternative matrix; preserves calcium-dependent pathways, but shows batch-to-batch variability and may interfere with some LC-MS methods.
• Citrate Plasma: 10% dilution from anticoagulant; good for coagulation-related metabolites; less common for general metabolomics.
• Serum: Clotting activates platelets and coagulation cascades, releasing metabolites; useful for specific applications but introduces variability.
• Fluoride/Oxalate: Glycolysis inhibitors that preserve glucose; not recommended for comprehensive metabolomics due to enzyme inhibition artifacts.

Serum metabolomics captures metabolites released during clotting, including platelet-derived factors and coagulation intermediates.[8] For studies of those processes, serum is optimal. But clotting adds temporal variability (typically 30–60 minutes of clot formation), during which continued cellular activity alters the profile. Human Serum applications include platelet metabolism, serotonin pathway analysis, and studies where clotting physiology is relevant.

Processing Speed and Temperature Control

Metabolite stability varies enormously across classes. Energy metabolites like ATP have half-lives measured in minutes, while structural lipids stay stable for hours at room temperature. Rapid processing that minimizes delay between phlebotomy and plasma separation is critical for preserving labile pools.[9] Our Human Plasma is processed within 30–60 minutes of collection, with immediate centrifugation at 4°C to slow enzymatic activity and prevent glycolysis and oxidation.

Blood cells left in contact with plasma keep metabolizing — consuming glucose, producing lactate, consuming oxygen, and releasing intracellular metabolites as membrane permeability changes. These ex vivo processes create artifactual shifts that misrepresent true circulating concentrations.[10] Rapid separation removes >99.9% of cells and halts these processes. Even cell-free plasma retains some enzymatic activity, so immediate freezing at −80°C arrests residual degradation, though some change occurs during freeze-thaw itself.

Metabolite Stability and Storage Considerations

Temperature affects metabolite stability at every step, from collection through long-term storage. Some metabolites tolerate room temperature for hours; others need immediate ice-water immersion.[11] Standard protocols typically use room-temperature transport followed by immediate cold processing, though specific analytes need alternatives. Ascorbic acid (vitamin C) oxidizes rapidly and needs metaphosphoric acid added at collection. Polyunsaturated fatty acids susceptible to peroxidation benefit from antioxidant addition (BHT, EDTA).

Metabolite Class-Specific Stability Considerations:

• Energy metabolites (ATP, ADP, AMP): Highly labile, degrade within minutes, require immediate freezing
• Glycolytic intermediates: Unstable; glycolysis continues ex vivo; fluoride/oxalate tubes or immediate processing essential
• Amino acids: Generally stable; can tolerate 1–2 hours at room temperature
• Lipids: Most classes stable, though polyunsaturated species oxidize slowly; antioxidants recommended
• Acylcarnitines: Stable in plasma for several hours
• Organic acids: Variable stability; some stable, others degrade within hours
• Methylated metabolites: Generally stable
• Nucleotides: Relatively unstable; rapid processing recommended
• Vitamins: Variable (vitamin C highly labile, vitamin D stable)

Freeze-thaw cycles progressively degrade many metabolites — through enzymatic activity during thaw, protein precipitation exposing metabolites to matrix effects, and physical stress causing fragmentation.[12] Single-use aliquots eliminate this variability. Small aliquots (50–200 μL) sized for specific assays avoid thawing an entire sample per analysis. Our Human Plasma is aliquoted into multiple small portions so longitudinal collections can be accessed repeatedly without freeze-thaw degradation.

Long-term storage stability also varies by class. Some species stay stable for decades at −80°C; others show detectable degradation within months. Periodic stability assessments on archived specimens document whether conclusions remain valid years after banking.[13] Quality control samples stored alongside research specimens enable monitoring through periodic re-analysis, with significant concentration changes prompting investigation of storage conditions or analytical drift.

Specimen Types for Metabolomics Applications

Plasma vs Serum Selection

Plasma is the preferred matrix for most metabolomics work — faster processing, no clotting-related artifacts, and better stability for many classes. The ~15% higher yield from plasma versus serum (serum excludes clotted volume) can be decisive when sample volume is limited.[14] EDTA plasma performs well across LC-MS and GC-MS platforms, with minimal ion suppression or chromatographic interference.

Serum is advantageous for specific applications where clotting releases biologically relevant metabolites, or where established clinical assays use serum. Lipidomics sometimes uses serum, since many lipid species tolerate clotting and historical lipid reference ranges were set in serum.[15] Serotonin studies may prefer serum, since platelets release serotonin during clotting, reflecting whole-blood content rather than the low levels in platelet-poor plasma.

Urine Metabolomics

Urine complements blood, enriched in water-soluble metabolites excreted renally and depleted in lipophilic species retained in circulation. It is less invasive than blood, enables longitudinal sampling without medical personnel, and captures kidney-filtered and secreted metabolites reflecting organ-specific processes.[16] Concentrations vary widely with hydration, so creatinine normalization corrects for dilution across samples and timepoints.

Urine Collection Considerations:

• First morning void preferred (overnight accumulation, consistent timing)
• Mid-stream clean catch minimizing bacterial contamination
• Immediate refrigeration or freezing after collection
• Centrifuge to remove particulates and cells before analysis
• Aliquot into small volumes for single-use
• Measure creatinine for normalization
• Record collection timing and any medications/supplements
• Avoid protease inhibitors (may interfere with downstream analyses)
• Store at −80°C for long-term banking

Tissue and Cellular Metabolomics

Tissue biopsies and isolated cells enable metabolomic analysis of specific cell types or organs, revealing compartment-specific metabolism invisible in bulk plasma. But ischemia after excision rapidly depletes energy metabolites and activates stress responses if processing is delayed.[17] Immediate snap-freezing in liquid nitrogen arrests metabolism within seconds. Human PBMCs metabolomics reveals immune cell metabolic changes in disease, with rapid processing and quenching essential for accurate energy-metabolite quantification.

Analytical Platform Considerations

Targeted vs Untargeted Metabolomics

Targeted metabolomics quantifies predefined panels using optimized methods with internal standards for absolute concentrations. It offers superior quantitative accuracy, lower detection limits, and excellent reproducibility — ideal for biomarker validation and clinical applications.[18] The trade-off is that it misses unexpected or novel metabolites outside the panel. Common targeted panels measure amino acids (20–40 species), acylcarnitines (20–60), organic acids (30–50), and biogenic amines including neurotransmitter metabolites.

Untargeted metabolomics uses high-resolution mass spectrometry to capture thousands of features without presupposing which metabolites are present. This discovery-oriented approach finds unexpected perturbations, novel biomarkers, and pathway alterations invisible to targeted methods.[19] The trade-offs: identification requires database matching and often remains tentative without confirmatory standards, and quantification is semiquantitative without internal standards. Untargeted workflows benefit from large sample sets for statistical power.

Sample Preparation Methods

Protein precipitation is the most common preparation method, using organic solvents (methanol, acetonitrile) to precipitate proteins while extracting small molecules into the supernatant. It is rapid, scalable, and compatible with most LC-MS platforms.[20] The downside is co-extraction of lipids, which can cause ion suppression in electrospray ionization. Solid-phase extraction (SPE) selectively enriches specific metabolite classes, improving sensitivity for targeted work at the cost of added complexity and sample.

Derivatization converts non-volatile metabolites into volatile derivatives for GC-MS, particularly valuable for organic acids, amino acids, and sugars. Common agents include trimethylsilyl and methoxime reagents.[21] It adds processing steps and potential artifacts, but enables orthogonal metabolome coverage complementing LC-MS.

Quality Control for Metabolomics Studies

Robust QC is essential given metabolomics’ sensitivity to pre-analytical variables and analytical drift. Pooled QC samples — created by combining small aliquots from all study specimens — provide matrix-matched controls spanning the full concentration range of the study population.[22] These pooled QCs, analyzed repeatedly throughout a batch, detect sensitivity drift, retention-time shifts, and other technical variation requiring correction before biological interpretation.

Essential QC Elements:

• Pooled biological QC samples analyzed every 8–12 injections
• Commercial reference standards for retention time and mass calibration
• Internal standards added to all samples correcting for extraction efficiency
• Blank injections detecting carryover or contamination
• Coefficient of variation monitoring (<20% for most metabolites)
• Principal component analysis identifying outlier samples
• Batch effect assessment and correction when multi-batch analysis required
• Normalization methods accounting for total signal intensity variations
• Missing value imputation strategies for below-detection-limit metabolites

External quality assessment programs enable cross-laboratory comparison, showing whether a lab’s results match field-wide consensus. Participation in proficiency testing documents analytical competence and surfaces systematic biases needing troubleshooting.[23]

Metabolite Databases and Pathway Analysis

Identifying metabolites from mass spectral data requires comprehensive databases cataloging neutral masses, fragmentation patterns, retention times, and collision cross-sections. HMDB (Human Metabolome Database), METLIN, and LipidMaps are gold-standard resources linking analytical signatures to chemical identities.[24] Many detected features still remain unidentified — unknown metabolites, drug metabolites, or environmental exposures not yet characterized.

Pathway analysis maps identified metabolites onto biochemical pathways, revealing coordinated regulation invisible from individual changes. KEGG, Reactome, and MetaboAnalyst enable statistical assessment of pathway-level perturbations.[25] Integration with transcriptomics and proteomics provides systems-level insight across molecular layers.

Disease-Specific Metabolomic Approaches

Cancer Metabolism

Cancer cells show profound metabolic reprogramming — the Warburg effect (aerobic glycolysis), glutamine addiction, and altered lipid metabolism supporting rapid proliferation. Plasma metabolomics from cancer patients reveals these systematic changes as circulating signatures, with elevated lactate, altered amino acid ratios, and perturbed lipids distinguishing cancer from controls.[26] Our Human Plasma from various cancer types shows disease-specific fingerprints correlating with tumor burden, stage, and treatment response.

Inborn Errors of Metabolism

Genetic defects in metabolic enzymes cause substrate accumulation and product deficiencies detectable through newborn screening and diagnostic metabolomics. Tandem mass spectrometry of dried blood spots or Human Plasma identifies dozens of inborn errors, including amino acidopathies, organic acidurias, and fatty acid oxidation disorders.[27] Carrier screening and prenatal testing use similar approaches.

Cardiovascular Disease

Metabolomic studies of cardiovascular disease identify circulating biomarkers predicting events years before clinical manifestation. Trimethylamine N-oxide (TMAO), generated from gut microbiota metabolism of dietary choline, associates with atherosclerosis risk. Branched-chain amino acids correlate with insulin resistance and diabetes risk.[28] Comprehensive lipidomics from Human Plasma or Human Serum reveals hundreds of lipid species with potential prognostic value.

Multi-Omic Integration

Modern systems biology combines metabolomics with genomics, transcriptomics, and proteomics to characterize biological states across molecular layers. Network analysis identifies correlations between metabolites, transcripts, and proteins, revealing regulatory relationships and feedback loops.[29] Machine learning models trained on multi-omic data predict phenotypes, classify disease subtypes, and forecast treatment responses with accuracy exceeding single-modality approaches. Multi-omic studies require careful specimen planning so all molecular layers are accessible — our Human Plasma, Human Serum, and Human PBMCs enable comprehensive multi-omic characterization from single collection events.

Check Our Inventory

Advancing metabolomics research with optimally processed biospecimens?

Sanguine offers Human Plasma and Human Serum collected and processed using metabolomics-optimized protocols. Rapid processing, controlled temperature, and comprehensive genomic annotation support cutting-edge metabolomic investigations from study design to receipt of samples.

Request a Custom Quote →

Ethical Sourcing and Regulatory Compliance

All Sanguine biospecimens are collected under IRB-approved protocols with comprehensive informed consent from every donor. Our HIPAA-compliant data management systems protect donor privacy while enabling researchers to access detailed genomic annotation supporting their studies. We maintain ISO 9001:2015 and ISO 13485:2016 certifications demonstrating our commitment to quality management across all operations.

Donor compensation follows ethical guidelines established by professional societies, ensuring voluntary participation without coercion. Geographic diversity in our collection network across the United States supports health equity in research while providing access to underrepresented populations often excluded from biomedical studies. Every specimen is designated Research Use Only (RUO) with clear documentation of its intended application scope.

References

1. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451-459. doi:10.1038/nrm.2016.25
2. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016;15(7):473-484. doi:10.1038/nrd.2016.32
3. Kamlage B, Maldonado SG, Bethan B, et al. Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. Clin Chem. 2014;60(2):399-412. doi:10.1373/clinchem.2013.211979
4. O’Sullivan A, Gibney MJ, Brennan L. Dietary intake patterns are reflected in metabolomic profiles. Am J Clin Nutr. 2011;93(2):314-321. doi:10.3945/ajcn.110.000950
5. Dallmann R, Viola AU, Tarokh L, et al. The human circadian metabolome. Proc Natl Acad Sci USA. 2012;109(7):2625-2629. doi:10.1073/pnas.1114410109
6. Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019;20(6):353-367. doi:10.1038/s41580-019-0108-4
7. Breier M, Wahl S, Prehn C, et al. Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples. PLoS One. 2014;9(2):e89728. doi:10.1371/journal.pone.0089728
8. Yin P, Lehmann R, Xu G. Effects of pre-analytical processes on blood samples used in metabolomics studies. Anal Bioanal Chem. 2015;407(17):4879-4892. doi:10.1007/s00216-015-8565-x
9. Wedge DC, Allwood JW, Dunn W, et al. Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? Anal Chem. 2011;83(17):6689-6697. doi:10.1021/ac201221h
10. Barri T, Dragsted LO. UPLC-ESI-QTOF/MS and multivariate data analysis for blood plasma and serum metabolomics: effect of experimental artefacts and anticoagulant. Anal Chim Acta. 2013;768:118-128. doi:10.1016/j.aca.2013.01.015
11. Pinto J, Domingues MR, Galhano E, et al. Human plasma stability during handling and storage: impact on NMR metabolomics. Analyst. 2014;139(5):1168-1177. doi:10.1039/c3an02188b
12. Fliniaux O, Gaillard G, Lion A, et al. Influence of common preanalytical variations on the metabolic profile of serum samples in biobanks. J Biomol NMR. 2011;51(4):457-465. doi:10.1007/s10858-011-9574-5
13. Anton G, Wilson R, Yu ZH, et al. Pre-analytical sample quality: metabolite ratios as an intrinsic marker for prolonged room temperature exposure of serum samples. PLoS One. 2015;10(3):e0121495. doi:10.1371/journal.pone.0121495
14. Hirayama A, Sugimoto M, Suzuki A, et al. Effects of processing and storage conditions on charged metabolomic profiles in blood. Electrophoresis. 2015;36(18):2148-2155. doi:10.1002/elps.201400600
15. Siskos AP, Jain P, Römisch-Margl W, et al. Interlaboratory reproducibility of a targeted metabolomics platform for analysis of human serum and plasma. Anal Chem. 2017;89(1):656-665. doi:10.1021/acs.analchem.6b02930
16. Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. PLoS One. 2013;8(9):e73076. doi:10.1371/journal.pone.0073076
17. Lin S, Hoffmann TJ, Storb R, et al. An optimized method for detection of primary and secondary metabolites in diverse biological matrices using gas chromatography time-of-flight mass spectrometry. Methods Mol Biol. 2014;1198:79-103. doi:10.1007/978-1-4939-1258-2_6
18. Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol. 2012;Chapter 30:Unit 30.2.1-24. doi:10.1002/0471142727.mb3002s98
19. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13(4):263-269. doi:10.1038/nrm3314
20. Bruce SJ, Tavazzi I, Parisod V, et al. Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography/mass spectrometry. Anal Chem. 2009;81(9):3285-3296. doi:10.1021/ac8024569
21. Fiehn O, Kopka J, Dörmann P, et al. Metabolite profiling for plant functional genomics. Nat Biotechnol. 2000;18(11):1157-1161. doi:10.1038/81137
22. Dunn WB, Broadhurst D, Begley P, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060-1083. doi:10.1038/nprot.2011.335
23. Siskos AP, Jain P, Römisch-Margl W, et al. Interlaboratory reproducibility of a targeted metabolomics platform for analysis of human serum and plasma. Anal Chem. 2017;89(1):656-665. doi:10.1021/acs.analchem.6b02930
24. Wishart DS, Feunang YD, Marcu A, et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. 2018;46(D1):D608-D617. doi:10.1093/nar/gkx1089
25. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr Protoc Bioinformatics. 2016;55:14.10.1-14.10.91. doi:10.1002/cpbi.11
26. Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336(6084):1040-1044. doi:10.1126/science.1218595
27. Chace DH. Mass spectrometry in newborn and metabolic screening. Chem Rev. 2001;101(2):445-477. doi:10.1021/cr990049d
28. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63. doi:10.1038/nature09922
29. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83. doi:10.1186/s13059-017-1215-1